Why It Matters
Invivyd Inc., a pharmaceutical company, reported $180,000 in combined third-quarter lobbying spending, including $120,000 through Forbes Tate Partners LLC. Its Oct. 20 disclosure lists health and infectious disease issues but names no specific legislation. The company's lobbying comes as it faces a major regulatory transition: The Food and Drug Administration (FDA) has notified Invivyd that the emergency use authorization for its COVID-19 monoclonal antibody PEMGARDA is scheduled to terminate June 29, 2027.
Invivyd develops monoclonal antibody therapies, a class of treatments that can provide immediate protection against viral infection but require significant manufacturing investment and may lose effectiveness as variants emerge. Its PEMGARDA product is authorized for COVID-19 prevention in certain immunocompromised patients, and the company is pursuing a regulatory pathway to maintain access beyond the scheduled emergency authorization termination.
By the Numbers
Forbes Tate Partners LLC reported $120,000 for Invivyd in the third quarter, according to its Oct. 20 filing. That matches the second-quarter figure of $120,000, up from $60,000 in the first quarter. Forbes Tate reported $0 for Invivyd in the fourth quarter of 2025. The firm's reported amount for Invivyd doubled from $60,000 in the first quarter to $120,000 in the second quarter.
Invivyd also files in-house. The company's in-house registrant reported $60,000 in the third quarter, listing lobbyist Ben Kenney. Combined, Invivyd's third-quarter lobbying spending across both registrants totaled $180,000. The client total held flat from the second quarter at $180,000, up from $80,000 in the first quarter and $20,000 in the fourth quarter of 2025.
King & Spalding LLP, which reported $0 for Invivyd in the first quarter, filed a termination in the second quarter and does not appear in the third quarter.
Two lobbyists named in the Forbes Tate filing are Zach Williams, a partner with no prior congressional staff experience listed in the cited record, and Barrett Thornhill, a former House staffer who served in the personal office of former Rep. Charles Norwood (R-GA). Invivyd's reported lobbying spending across the past four quarters totals $460,000.
Broader Context
The Centers for Disease Control and Prevention (CDC) updated its guidance in October to recommend a 2026-27 COVID-19 vaccine for all adults ages 18 and older, as CIDRAP reported. The recommendation also covers children ages 6 months through 17 years with moderate to severe immunocompromise, while vaccination for other children in that age group is recommended through shared clinical decision-making. CDC notes that some recommended uses fall outside FDA-approved indications.
Separately, Deputy Health and Human Services Secretary Jim O'Neill, acting as CDC director, signed a memorandum Jan. 5 accepting recommendations to revise the childhood immunization schedule. However, a federal court stayed the memorandum on March 16 in American Academy of Pediatrics v. Kennedy, leaving the July 2025 childhood immunization schedule in effect, according to CDC.
Invivyd also faces a regulatory transition affecting its COVID-19 monoclonal antibody PEMGARDA (pemivibart). On July 6, the company announced that the FDA had notified it that PEMGARDA's emergency use authorization would terminate June 29, 2027, following the planned end of the federal COVID-19 emergency use declaration. Invivyd said it was discussing next steps with FDA and seeking a pathway to continued availability. Its next-generation antibody candidate, VYD2311, is also under clinical development. These developments provide company-specific context for its federal health policy interests, although its lobbying disclosure does not identify the PEMGARDA authorization as a lobbying target.
On the legislative front, the House introduced H.R. 7352, the PASTEUR Act, in February. Its reported Senate companion, S. 4875, was introduced June 23 and referred to the Senate Health, Education, Labor and Pensions (HELP) Committee. The legislation concerns federal incentives for antimicrobial development, a distinct area of infectious disease policy from Invivyd's monoclonal antibody products. The company does not identify either bill in its lobbying disclosure.
Sen. Tammy Baldwin (D-WI) introduced S. 4451, the Wildlife Health Coordination and Zoonotic Disease Prevention Act, on April 30. The cited legislative account reports that the Senate Environment and Public Works Committee referred it, with no cosponsors or subsequent action recorded as of the filing date.
A 2025 analysis in the journal mAbs argues that pandemic preparedness should include monoclonal antibody research and development, regional manufacturing capacity, and collaborative development and distribution networks. The analysis notes that monoclonal antibodies can provide immediate protection but are costly and complex to manufacture, offer only temporary protection, and may lose effectiveness as viral variants emerge.
The CDC's October issue of Emerging Infectious Diseases reported that Bundibugyo virus disease reemerged in May as a cross-border outbreak involving Uganda and the Democratic Republic of the Congo, with no licensed vaccine or therapeutic available. The report documented 20 confirmed cases in Uganda as of July 8, including 15 imported cases and five locally transmitted cases, with a 15% case-fatality rate. The outbreak illustrates the broader infectious disease landscape, although Invivyd's filing does not identify Bundibugyo virus disease as a lobbying issue.
The Bottom Line
Invivyd's most direct regulatory decision point is the scheduled June 29, 2027, termination of PEMGARDA's emergency use authorization and the company's discussions with FDA about continued availability. Senate HELP Committee consideration of S. 4875, the reported PASTEUR Act companion, remains a separate legislative development, with no direct connection to Invivyd's disclosed lobbying established.
Access the Legis1 platform for comprehensive political news, data, and insights
Spot something wrong? Report an issue with this article
